This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics. IBRANCE® (palbociclib) Prescribing Information for the UK click here. Adverse event reporting information can be found at the bottom of the page.
IBRANCE® is indicated for the treatment of patients with HR+/HER2– locally advanced or metastatic breast cancer and is suitable for pre-, peri- or postmenopausal women. IBRANCE® should be used in combination with an AI or in combination with fulvestrant in women who have received prior endocrine therapy. For pre- or perimenopausal women, the endocrine therapy should be combined with an LHRH agonist.1
Click for more information on the Randomised controlled trial PALOMA-2, Real world evidence
P-REALITY X studies
Click here for Safety Information.
Click to return to Patient Profiles or to visit Allison.
This is a fictional patient and images are illustrative only.
*Data cut-off: 31 May 2017. In PALOMA-2, the primary endpoint was investigator-assessed PFS.2
†PALOMA clinical trials. Based on pooled data from 872 patients who received IBRANCE® in combination with ET (n=527 in combination with letrozole and n=345 in combination with fulvestrant).2,3 ‡ROIS (N=191) and IRIS UK cohort (N=255). Safety data were not reported in P-REALITY X.4,5
§ IBRANCE® should be taken for 3 weeks on and 1 week off, in combination with either an AI or fulvestrant 500 mg IM. In pre- or perimenopausal women, the ET should be combined with an LHRH agonist.
||Full blood count should be monitored prior to the start of IBRANCE® therapy and at the beginning of each cycle, as well as on Day 15 of the first two cycles, and as clinically indicated.1
‡All patients should also be monitored for pulmonary symptoms indicative of ILD/pneumonitis, signs and symptoms of infection, deep vein thrombosis and pulmonary embolism. Patients with moderate or severe hepatic and renal impairment should be closely monitored for signs of toxicity.1
AI : aromatase inhibitor
CI: confidence interval
ET : endocrine therapy
HER2 : human epidermal growth factor receptor 2
HER2—: human epidermal growth factor receptor 2-negative
HR+: hormone receptor positive
HR : hormone receptor
IM : intramuscular
IRIS: IBRANCE real-world insights
LHRH : luteinising hormone-releasing hormone
mBC : metastatic breast cancer
mPFS : median progression-free survival
PFS : progression-free survival
P-REALITY X : palbociclib real-world first-line comparative effectiveness study extended
PSM : propensity score matching
QoL : quality of life
RCT : randomised controlled trial
RWE : real world evidence
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.